Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
Follow this Marathon quest walkthrough to help you complete every step of the Data Reconstruction Priority Contract for ...
Researchers warn that a newly identified open-source AI security testing platform called CyberStrikeAI was used by the same threat actor behind a recent campaign that breached hundreds of Fortinet ...
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
By Kanishka Singh WASHINGTON, March 2 (Reuters) - The U.S. Interior Department said a database revealing how President Donald Trump's administration planned to revise information on key phases of ...
A draft assessment of the health of nature in the United States is grim but shot through with bright spots and possibility. By Catrin Einhorn An unusual outbreak of wildfires in city parks gave ...
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results